Page 5,508«..1020..5,5075,5085,5095,510..5,5205,530..»

Florida Hospital Tampa Outpatient Therapy Center is Celebrating a Successful First Year as the only Tampa Bay Provider …

Posted: Published on March 29th, 2013

Therapy programs provide real results for speech, voice and physical movement for Parkinsons Disease patients and offer hope for Stroke, Multiple Sclerosis, Cerebral Palsy and Downs Syndrome patients (PRWEB) March 29, 2013 The occupational therapy component works on fine motor skills like writing, getting dressed and doing basic household chores. This therapy helps our patients manipulate zippers and buttons so they have more clothing options like wearing regular trousers, and they are no longer limited to wearing elastic waistband pants, said Erik Spahn, Certified Occupational Therapist at Florida Hospital Tampa. LSVT LOUD improves vocal loudness by stimulating the muscles of the voice box (larynx) and speech mechanism through a systematic hierarchy of exercises. This program improves breathing, swallowing and talking clearly. The treatment does not train people for shouting or yelling; it actually helps patients reach a healthy vocal loudness with no strain. While LSVT LOUD has been successfully administered to individuals in all stages of PD, the treatment is most effective among those who are in early or middle stages of the condition. Recently, LSVT LOUD is being applied to select individuals with stroke, multiple sclerosis, Downs syndrome and cerebral palsy with positive outcomes. The therapy program consists of … Continue reading

Posted in Cerebral Palsy Treatment | Comments Off on Florida Hospital Tampa Outpatient Therapy Center is Celebrating a Successful First Year as the only Tampa Bay Provider …

New Research From Mount Sinai on the Effects of Traumatic Brain Injury (TBI) in Older Adults

Posted: Published on March 29th, 2013

Considerable opportunity exists to improve interventions and outcomes of traumatic brain injury (TBI) in older adults, according to three studies published in the recent online issue of NeuroRehabilitation by researchers from the Icahn School of Medicine at Mount Sinai. New York, NY (PRWEB) March 28, 2013 Some evidence suggests that a history of TBI is associated with an increased risk of dementia later in life, but the clinical features of dementia associated with TBI have not been well investigated. Researchers at the Icahn School of Medicine as well as other institutions analyzed data from elderly individuals with dementia with and without a history of TBI to characterize the clinical profiles of patients with post-TBI dementia. The results of the study indicate that compared to older adults with dementia with no history of TBI, those with a history of TBI had higher fluency and verbal memory scores and later onset of decline. However, their general health was worse, they were more likely to have received medical attention for depression, and were more likely to have a gait disorder, falls, and motor slowness. These findings suggest that dementia among individuals with a history of TBI may represent a unique clinical phenotype that … Continue reading

Posted in Brain Injury Treatment | Comments Off on New Research From Mount Sinai on the Effects of Traumatic Brain Injury (TBI) in Older Adults

Gaps Exist in Brain Injury Knowledge Among Veterans

Posted: Published on March 29th, 2013

Newswise Researchers at the University of Alabama at Birmingham (UAB) found that only 1 in 5 veterans reported receiving brain injury education while serving in the military. The researchers, whose findings were published this week in the Journal of Head Trauma Rehabilitation, believe a lack of accurate knowledge could lead to misdiagnosis or misinterpretation due to the many symptoms that can overlap among brain injury and other conditions like post-traumatic stress disorder (PTSD), depression and chronic pain. The ultimate risk in misinterpretation is that the patient may be treated in a different direction from where they need to go, said Cady Block, primary investigator of the study and doctoral student with the UAB Department of Psychology. In the case of a veteran who sustains a brain injury, for example, they may be deemed to be disabled instead of integrating back into their community and their job. That direction of treatment may not look at encouraging ways to give them their life back. The study looked at 100 veterans and 50 of their friends or family. It found that both groups were able to correctly identify symptoms associated with mild brain injury. However, both groups endorsed numerous symptoms that are not … Continue reading

Posted in Brain Injury Treatment | Comments Off on Gaps Exist in Brain Injury Knowledge Among Veterans

New Research on the Effects of Traumatic Brain Injury (TBI) in Older Adults

Posted: Published on March 29th, 2013

Newswise Considerable opportunity exists to improve interventions and outcomes of traumatic brain injury (TBI) in older adults, according to three studies published in the recent online issue of NeuroRehabilitation by researchers from the Icahn School of Medicine at Mount Sinai. An Exploration of Clinical Dementia Phenotypes Among Individuals With and Without Traumatic Brain Injury Some evidence suggests that a history of TBI is associated with an increased risk of dementia later in life, but the clinical features of dementia associated with TBI have not been well investigated. Researchers at the Icahn School of Medicine as well as other institutions analyzed data from elderly individuals with dementia with and without a history of TBI to characterize the clinical profiles of patients with post-TBI dementia. The results of the study indicate that compared to older adults with dementia with no history of TBI, those with a history of TBI had higher fluency and verbal memory scores and later onset of decline. However, their general health was worse, they were more likely to have received medical attention for depression, and were more likely to have a gait disorder, falls, and motor slowness. These findings suggest that dementia among individuals with a history of … Continue reading

Posted in Brain Injury Treatment | Comments Off on New Research on the Effects of Traumatic Brain Injury (TBI) in Older Adults

New research on the effects of traumatic brain injury

Posted: Published on March 29th, 2013

Public release date: 28-Mar-2013 [ | E-mail | Share ] Contact: Mount Sinai Press Office NewsMedia@mssm.edu 212-241-9200 The Mount Sinai Hospital / Mount Sinai School of Medicine Considerable opportunity exists to improve interventions and outcomes of traumatic brain injury (TBI) in older adults, according to three studies published in the recent online issue of NeuroRehabilitation by researchers from the Icahn School of Medicine at Mount Sinai. An Exploration of Clinical Dementia Phenotypes Among Individuals With and Without Traumatic Brain Injury Some evidence suggests that a history of TBI is associated with an increased risk of dementia later in life, but the clinical features of dementia associated with TBI have not been well investigated. Researchers at the Icahn School of Medicine as well as other institutions analyzed data from elderly individuals with dementia with and without a history of TBI to characterize the clinical profiles of patients with post-TBI dementia. The results of the study indicate that compared to older adults with dementia with no history of TBI, those with a history of TBI had higher fluency and verbal memory scores and later onset of decline. However, their general health was worse, they were more likely to have received medical attention … Continue reading

Posted in Brain Injury Treatment | Comments Off on New research on the effects of traumatic brain injury

FDA approves new oral MS drug, Tecfidera

Posted: Published on March 29th, 2013

U.S. regulators on Wednesday approved a new multiple sclerosis drug made by Biogen Idec Inc that is widely expected to become the No. 1 oral treatment for the disease, with annual sales topping $3 billion. The drug, Tecfidera, activates a chemical pathway in the body known as Nrf2 that helps protect nerve cells from damage and inflammation. Following Wednesday's approval by the Food and Drug Administration, Biogen said it will launch the drug within the coming days. Multiple sclerosis is a chronic condition that attacks the central nervous system and can lead to numbness, weakness, paralysis and blindness. It affects more than 2.1 million people worldwide, according to the National Multiple Sclerosis Society. "We expect a solid launch of Tecfidera, and our sense is that there is a bolus of patients in the queue ready to transition to therapy," Geoff Meacham, an analyst at J.P. Morgan, said in a research note. "However, we believe that Street expectations likely already account for this and then some." Shares of Weston, Massachusetts-based Biogen rose 3.2 percent to close at $182.68 on Wednesday. The shares have more than tripled over the past three years, mainly driven by high hopes for Tecfidera, known chemically as … Continue reading

Posted in MS Treatment | Comments Off on FDA approves new oral MS drug, Tecfidera

The Greatest Thing Since Sliced Bread Has Arrived for MS Patients

Posted: Published on March 29th, 2013

Last November, I examined five experimental drugs that appeared as if they had all of the tools necessary to become life-changing blockbusters from a financial and quality of life perspective. Yesterday, the first experimental drug I highlighted from Biogen Idec (NASDAQ: BIIB) was approved by the Food and Drug Administration as a first-line treatment for relapsing MS. Pardon the cliche, but I believe the greatest thing since sliced bread has just been bestowed upon MS patients whether they realize it yet or not. Greater efficacy with fewer side effects is possible! Tecfidera -- previously known as BG-12 in trials -- was studied in two different clinical trials known as Confirm and Define. In its Confirm study, Biogen noted that its pill, administered twice daily, reduced the rate of MS relapses by an impressive 49%, and was associated with a 71% to 99% drop in new or expanding lesions in both trials. What's truly unique about Tecfidera is its adverse events profile, which demonstrates the promise of fewer side effects with better efficacy. The most common side effects exhibited by patients on Tecfidera were flushing and gastrointestinal events, which often resulted in very low trial dropout rates. Biogen's new medication could … Continue reading

Posted in MS Treatment | Comments Off on The Greatest Thing Since Sliced Bread Has Arrived for MS Patients

Oral treatment for MS excites patients

Posted: Published on March 29th, 2013

BUFFALO, N.Y. (WIVB) - Steve Waschensky has had multiple sclerosis for 26 years. He participated in the trial of Avonex, the first successful treatment, and he's been taking it ever since. But those injections have side effects. "Headaches for about 24 hours, basically a headache and a slight fever," he said. Now an oral drug called Tecfidera was just approved by the FDA. It was also tested in Buffalo, and it's very effective in three important areas. Dr. David Hojnacki of the Jacobs Neurological Institute said, "Reducing relapses, reducing accumulation of new MRI lesions in the brain, as well as reduction in disability progression." Doctors use MRI scans to follow the course of MS. Bright white areas are MS lesions, and they typically enlarge and increase in number during the disease, but the drug reduced that. It also has very few side effects. "We haven't had a good oral option, and now I think we really do. The phones have been ringing here in our office. Now that this drug has been approved there's been excitement among our patients and a lot of anticipation of this drug becoming available, and now it's here," Dr. Hojnacki said. Sign Waschensky up! "Oh, … Continue reading

Posted in MS Treatment | Comments Off on Oral treatment for MS excites patients

Run helps young man with rare disease

Posted: Published on March 29th, 2013

BAKERSFIELD, Calif. - This weekend you can help spread awareness for a disease that is robbing children of their lives. Saturday is the 7th annual Rabbit Run and Bunny Run for the Friedreich's Ataxia Research Alliance at Yokuts Park in Southwest Bakersfield. The 5K/10K run/walk will raise money to research the mysterious disease that slowly deteriorates the body's muscle tissue. Currently there is no treatment or cure for the lethal disease that impacts one in every 50,000 people around the country. 23ABC sat down with Jerod Laird, a local young man with the rare disease, and his mother Carrie Laird to talk about the debilitating diagnosis. Carrie explained, "in the last five years it's changed a lot. Jerod was walking full time a year ago and he's now in a wheelchair fulltime." But through it all Jerod has always kept his spirits high with a grin on his face. "I feel good, I always feel good" the now 25-year-old said. This weekends run/walk starts Saturday at 8am at Yokuts Park. Children cost $15 and adults are $35. More: Run helps young man with rare disease … Continue reading

Comments Off on Run helps young man with rare disease

Edison Pharmaceuticals, Inc. signs licensing agreement with Dainippon Sumitomo Pharma Co., Ltd. for development …

Posted: Published on March 29th, 2013

MOUNTAIN VIEW, Calif., March 28, 2013 /PRNewswire/ --Edison Pharmaceuticals today announced that it has entered into a research/development and commercialization agreementwithDainippon Sumitomo Pharma Co., Ltd. (DSP) for the development of EPI-743 and EPI-589 in Japan. Under the terms of the agreement, DSP will gain development and commercialization rights in Japan in exchange for Edison receiving $35 million in upfront and $15 million in R&D support. In addition, Edison will be eligible to receive $10-35 million in development milestones per indication and up to $460M in commercial milestone payments as well as royalties on commercial sales. The initial scope of the transaction includes bothpediatric orphan inherited mitochondrial andadult central nervous system diseases. Under the terms of the agreement, DSP will undertake activities required for development, approval, and commercialization of EPI-743 in Japan. The work willinitially focus on orphan pediatric mitochondrial disease. Edison will retain 100% ownership and direct all research, clinical, and commercial development of EPI-743 and EPI-589 outside of Japan. In addition, the parties will collaborate on the research and development of EPI-589 with a focus on adult central nervous system disease. This collaboration is based upon the emerging body of data implicating redox and mitochondrial dysfunction as a root … Continue reading

Comments Off on Edison Pharmaceuticals, Inc. signs licensing agreement with Dainippon Sumitomo Pharma Co., Ltd. for development …

Page 5,508«..1020..5,5075,5085,5095,510..5,5205,530..»